Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target

Wedbush analyst David Nierengarten has reiterated an Outperform rating on Bicara Therapeutics (NASDAQ: BCAX) and has maintained a price target of $30 for the stock. No additional financial figures or strategic changes were mentioned in the article.